The treatment regimen achieved a 100% overall response rate, with 95% of patients reaching complete response after brexucabtagene autoleucel infusion. Safety concerns included cytokine release ...

Researchers at ASH shared Phase III data comparing the pre- and five-year post-treatment adjusted annualized bleeding rates, ...

Research presented at the 2025 ASH Annual Meeting sheds light on serious side effects that appear weeks or months after CAR T cell therapy for multiple myeloma.

Bank of America Home Care Conference December 8, 2025 10:50 AM ESTCompany ParticipantsMeenal Sethna - Executive VP ...

FRISCO, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today the appointment of Jody Thompson to ...

Remicade, the brand name for infliximab, is an intravenous biologic therapy for conditions such as Crohn's disease, ...

Vice President of Froedtert Holy Family Memorial Hospital says they've seen significant growth in demand for specialty infusion services.

Bank of America Leveraged Finance Conference December 2, 2025 10:50 AM ESTCompany ParticipantsNicole Maggio - Senior ...

The National Home Infusion Association (NHIA) says 10 new cosponsors have signed onto the Protecting Patient Access to Home ...

Monroe Capital LLC ("Monroe") announced it acted as sole lead arranger and administrative agent on the funding of a senior credit facility to support the acquisitions of Reliant Healthcare ("Reliant") ...

Reliant Healthcare has been recapitalized by Shore Capital Partners and merged with Care Fusion Rx. The combined company will unite Reliant’s established presence across the South with Care Fusion’s ...

Shore Capital Partners ("Shore" or "Shore Capital"), a Chicago-based private equity firm with offices in Nashville, today announced the merger of Reliant Healthcare ("Reliant") and Care Fusion Rx ...